New York, NY -- (SBWIRE) -- 01/07/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Myriad Genetics, Inc (NASDAQ:MYGN), ProShares UltraShort DJ-UBS Crude Oi ETF (NYSEARCA:SCO), NPS Pharmaceuticals, Inc (NASDAQ:NPSP), Yandex NV (NASDAQ:YNDX)
Myriad Genetics, Inc (NASDAQ:MYGN) showed a volume of 1.82 million shares by the end of last trade whereas the average volume of the stock remained 2.69 million shares. The stock opened the session at $21.19 but then moved to $21.03. At that price, the stock showed a negative performance of -0.08%. Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis.
Will MYGN Get Buyers Even After The Recent Rally? Find Out Here
ProShares UltraShort DJ-UBS Crude Oi ETF (NYSEARCA:SCO) opened the session at $34.69 and closed the session at $34.81. The stock showed a positive performance of 1.13% in previous trading session.
For How Long SCO will fight for Profitability? Read This Trend Analysis report
NPS Pharmaceuticals, Inc (NASDAQ:NPSP) opened the session at $32.94 and closed the session at $31.86. The stock showed a negative performance of -1.64% in previous trading session. The beta of the stock remained 0.46. NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The Company’s primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved by the United States Food and Drug Administration (FDA) during the year ended December 31, 2012, for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support.
Why Should Investors Buy NPSP After the Recent Fall? Just Go Here and Find Out
Yandex NV (NASDAQ:YNDX) the stock advanced 0.02% and finished the session at $42.91. Traded with volume of 1.81 million shares in the prior session and the average volume of the stock remained 2.40 million shares. Yandex N.V. (Yandex) is an Internet company in Russia. During the year ended December 31, 2011, the Company generated 63.3% of all search traffic in Russia, and 60.6% in December 2011, and its Yandex sites attracted 45 million visitors in December 2011. It also operates in Ukraine, Kazakhstan, Belarus and Turkey. Yandex also aggregates and organizes local, national and international content and offers a range of additional services. Its search and a number of its services are location-based and are available in versions tailored for mobile and other digital platforms and devices.
Will YNDX Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)